During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Fatty liver disease, the excessive lipid accumulation in the liver, is a frequent metabolic condition that can progress in cancer. Despite years of research, targeted treatments are still lacking and ...

D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...

In addition to this, we also assessed the prognostic values of these alterations, and specifically in the HER2-positive breast cancer brain metastasis, we observed that the presence of PIK3CA ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Objective: Capivasertib, a novel pan-AKT inhibitor, shows significant antitumor activity against hormone receptor-positive advanced breast cancer. However, its cost-effectiveness of this treatment ...

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors - Beyond the Abstract Marta ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

called phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and a widely studied pro-tumorigenic transcription factor, called androgen receptor (AR). However, no therapies exist to ...

called phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and a widely studied pro-tumorigenic transcription factor, called androgen receptor (AR). However, no therapies exist to ...

called phosphatase and tensin homologue deleted on chromosome 10 (PTEN), and a widely studied pro-tumorigenic transcription factor, called androgen receptor (AR). However, no therapies exist to ...